TriGemX Bio
TriGemX Bio is advancing Elismetrep, a Phase 3 investigational therapy for the acute treatment of migraine, targeting previously unexplored neural networks implicated in migraine pathophysiology. The company aims to provide rapid and effective relief while addressing limitations of current acute treatments, such as delayed onset and cardiovascular contraindications.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Raised to date
$581.2MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
$338.2M across 3 disclosed rounds
BMTCVG$94M · Undisclosed
Announced Oct 2026 · from article date
Disclosed cumulative: $338.2M
Reported total $581.2M
Incomplete round history. $243M of the $581.2M reported total isn’t matched to a known round.
Founders
Founder details are not available yet.
Product
Problem
Migraine is a prevalent neurological disorder with significant unmet need for acute treatments that are both effective and well-tolerated. Many existing acute migraine therapies have limitations including delayed onset of action, cardiovascular contraindications, or inadequate pain relief for a substantial proportion of patients.
Solution
TriGemX Bio is advancing Elismetrep, a novel investigational therapy currently in Phase 3 clinical development for the acute treatment of migraine. The company's approach is grounded in foundational research into previously unexplored neural networks involved in migraine pathophysiology. By targeting these specific pathways, Elismetrep aims to provide rapid and effective relief from migraine attacks. The company is led by a team of experienced drug developers who are translating these scientific insights into a viable therapeutic candidate with the potential to address the limitations of current treatment options.
Target Audience
The primary customers are healthcare providers and patients seeking acute migraine treatments, with the ultimate commercial audience being neurologists, headache specialists, and the broader migraine patient population.
Features
- Elismetrep is a Phase 3-stage investigational asset specifically developed for the acute treatment of migraine
- Therapeutic approach based on research into previously unexplored neural networks implicated in migraine
- Pipeline focused on delivering cutting-edge solutions for challenging neurological diseases
- Development program led by a team combining scientific innovation with real-world drug development experience